Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Non Operating Income data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 85.99% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (up 47.48% YoY), and the FY2025 full-year result was $9.3 million, up 25.06% from the prior year.
• Non Operating Income retreated to $2.1 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.6 million in Q2 2025 to a low of $165000.0 in Q3 2023.
• A 5-year average of $1.5 million and a median of $1.4 million in 2025 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income slumped 61.36% in 2023 and surged 1144.85% in 2024, its largest moves.
• Tracing LXEO's Non Operating Income over 5 years: stood at $620000.0 in 2022, then increased by 26.94% to $787000.0 in 2023, then soared by 85.26% to $1.5 million in 2024, then soared by 50.69% to $2.2 million in 2025, then declined by 2.73% to $2.1 million in 2026.
• Business Quant data shows LXEO's Non Operating Income at $2.1 million in Q1 2026, $2.2 million in Q4 2025, and $1.4 million in Q3 2025.